A Comprehensive Gas Chromatography Procedure for Measurement of Drugs in Biological Materials

Total Page:16

File Type:pdf, Size:1020Kb

A Comprehensive Gas Chromatography Procedure for Measurement of Drugs in Biological Materials Annals of Clinical and Laboratory Science, Vol. 5, N o. 1 Copyright © 1975, Institute for Clinical Science A Comprehensive Gas Chromatography Procedure for Measurement of Drugs in Biological Materials JAMES R. SHIPE, B.S. AND JOHN SAVORY, Ph .D. Division of Clinical Chemistry, Departments of Medicine, Biochemistry and Pathology and Hospital Laboratories, The University of North Carolina, Chapel Hill, NC 27514 ABSTRACT Procedures have been developed for the determination in serum and urine of 21 drugs which include all of the barbiturates, methyprylon, glutethimide, meprobamate, propoxyphene, methaqualone, primidone, diphenylhydantoin, methadone, codeine, morphine, amphetamine and methamphetamine. The method involves pipeting 1.0 ml of serum or urine into an extraction tube, adding an internal standard together with either a pH 4.9 or pH 8.3 buffer and extracting with chloroform. The drugs in the extract are concentrated by evaporation of the organic layer and identified and quantitated by gas-liquid chromatography (GLC) using a column packed with 3 percent OV 17. GLC analysis times are kept below seven minutes by using temperature program­ ming which allows good separations of drugs of widely varying volatilities. All calculations are based on peak areas determined by an electronic inte­ grator. Losses of drugs during extraction, evaporation and chromatography steps are compensated for by the use of internal standards. Actual extraction efficiencies of drugs from serum or urine range from 75 to 100 percent although recoveries, based on standards carried through the entire procedures, are quantitative. Precision (s.d.) based on replicate determinations is approx­ imately ± 0.2 mg per dl. Introduction the final analytical measurement of drugs. Increasing emphasis is being placed on Resolution of different compounds is ex­ identification and quantitation of drugs in cellent, low limits of detection are possible patients suspected of overdose. In addition, and the technique affords high precision. the monitoring of therapeutic levels of a Numerous reports have been made of number of drugs, especially those in the the measurement of individual drugs or antiepileptic category, is of considerable groups of drugs using gas chromatographic importance.7’9’13 techniques.1’3’4’6’10’11’12 However, the clin­ For most clinical laboratories, gas chro­ ical laboratory scientist has the problem of matography offers the best technique for making a selection from this wide variety 57 5 8 SHIPE AND SAVORY TABLE I chromatographic conditions are outlined in Gas Chromatographic Conditions table I. Carrier gas N2 45 ml per min C o l u m n s Hydrogen flow rate 50 ml per min Air flow rate 1.4 cubic ft per hr Glass U-shaped columns 3 ft X 2 mm in­ Detector temperature 250° C ternal diameter are packed with 3 percent Infector temperature 230° C OV-17 on Gas-Chrom Q 100-120 mesh. This packing is available commercially. § Column temperature Sedatives 140 to 240° C The columns are conditioned with normal program at 20° per min Amphetamines 150° C isothermal carrier gas flow by heating at 100° for one Alkaloids 240° C isothermal hour and increasing the temperature 2° per Electrometer range 200 on Model 2600 minute up to 240°. This final temperature Chart speed 1 in per min is maintained for 18 hours. Columns condi­ Recorder Fall scale range - 1 mV tioned in this manner will give excellent resolution for approximately one year. of methods to fulfill the needs of his labo­ S o l v e n t E v a p o r a t io n B a t h ratory. A fairly comprehensive approach to drug measurements was reported by Bar­ A water bath maintained at 75° is used rett1 and involved the determination of the to evaporate solvents following extractions. barbiturates, glutethimide, amphetamines, Nitrogen is used to aid the evaporation and alkaloids and the common tranquilizers. is supplied through a glass manifold and The present study uses most of the basic directed into the evaporation tubes through methodology described by Barrett but also Pasteur pipets. involves several modifications which in­ clude temperature programming for drug R eagen ts screening purposes and for monitoring B arbiturates , N e u t r a l s , || D il a n t i n therapeutic levels of the antiepileptic drugs. Sodium acetate buffer ( 1.0 M, pH 4.8). Precisely 410 ml of 1.0 N acetic acid and Special Apparatus 590 ml of 1.0 N sodium acetate are mixed and the pH adjusted to 4.8 with either G a s C hromatograph acetic acid or sodium acetate. A dual-column instrument* equipped Barbital internal standard. A stock solu­ with dual hydrogen flame ionization de­ tion of 100 mg per 100 ml is made up in tectors, dual electrometers and linear tem­ methanol. perature programming is employed. This Buffer (containing internal standard). system is coupled to two strip chart re­ Two ml of the barbital internal standard corders f and an electronic digital inte­ stock solution are diluted to 100 ml with grator equipped with a printer, j The gas acetate buffer. Diphenylhydanoin internal standard. A ° Model 2600 Bendix Corporation, Process In­ struments Div., Drawer 477, Ronceverte, WV stock solution is prepared by dissolving 100 24970. f Model SRG, Sargent-Welch Scientific Co., § Applied Science Laboratories, Inc., P.O. Box 7300 N. Linder Ave., Skokie, IL 60076. 440, State College, PA 16801. | Model 6230, Vidar Autolab, 77 Ortega Ave., || Neutrals are those drugs which extract at any Mountain View, CA 94040; NOW Div. of Spectra- pH. Those commonly encountered in the clinical Physics, 655 Clyde Ave., Mountain View, CA laboratory are: methyprylon, gluthethimide, and «4040. meprobamate. DRUG MEASUREMENT IN BIOLOGICAL MATERIALS BY GAS CHROMATOGRAPHY 5 9 mg 5-(p-methylphenyl)-5-phenyl hydan- S t a n d a r d S o l u t io n s toinfi in 100 ml of chloroform. Sedative slock standards. The pure drugs Chloroform (containing Dilantin inter­ were obtained from the appropriate manu­ nal standard). Two ml of the stock Dilan­ facturer. A stock standard of each of the tin internal standard are diluted to one following drugs was prepared by dissolv­ liter with redistilled chloroform. ing 100 mg (if present as sodium salt, Trimethylanilinium hydroxide (TMAH) volume weight for free acid must be in methanol ( 0.2 M ). Thirty ml of N, N- corrected) of each compound in 100 ml dimethyl aniline* are dissolved in 200 ml of methanol: methyprylon, aprobarbital, of ethyl acetate and added to 25 ml of butabarbital, amobarbital, pentobarbital, methyl iodide. The reaction mixture is al­ secobarbital, glutethimide, propoxyphene, lowed to stand overnight at room tempera­ methaqualone, phenobarbital, primidone, ture and the product, N,N, N-trimethylani- diphenylhydantoin, flurazepam. line iodide, recovered by filtration followed Sedative working standards. One ml of by recrystallization from hot absolute eth­ each of the stock sedative standards is anol. Exactly 5.2 g of the iodide are dis­ combined and diluted to 100 ml with solved in 100 ml of absolute methanol to water. The final concentration of each drug which are added 3.5 g of powdered silver is then one mg per 100 ml. oxide. The slurry is mixed at room temper­ Stock amphetamine standards (2.5 mg ature for one hour and the silver iodide per 100 ml). Exactly 42.75 mg of ampheta­ removed by filtration. The TMAH reagent mine sulfate and 31.10 mg of methamphet- is then stored in a 120 ml ground-glass amine HC1 are dissolved in one liter of stoppered bottle. water. Stock alkaloid standards (100 mg per 100 m l). Each of the following compounds is A l k a l o id s a n d A mphetamines dissolved in 100 ml of water: 131.6 mg Borate buffer (pH 8.3). A saturated so­ codeine phosphate, 133.6 mg morphine sul­ lution of sodium borate is adjusted to pH fate and 100 mg methadone. 8.3 with 2 N NaOH. Alkaloid and amphetamine working stan­ Amphetamine internal standard. Five mg dards. One ml of each of the stock alka­ N-propylamphetamine HClf are dissolved loids is combined with 20 ml of the am­ in 100 ml of water. phetamine stock standard and diluted to 100 ml with water. The final concentration Alkaloid internal standard. Five hundred of each alkaloid is then one mg per 100 ml mg of nalorphine hydrochloride are dis­ and 0.5 mg per 100 ml for the ampheta­ solved in 100 ml of water. mines. 'Nalorphine buffer. One ml of the stock nalorphine internal standard is diluted to Procedures 100 ml with borate buffer. S e d a t iv e a n d A nticonvulsant D r u g s Re-distilled acetic anhydride. Reagent grade acetic anhydride is distilled through One ml of serum or standard, one ml of a 12 inch Vigreaux column. acetate buffer and 10 ml of chloroform are added to a 15 ml ground-glass stoppered If Aldrich Chemical Co., Inc. centrifuge tube. For diphenylhydantoin de­ * Eastman Kodak. terminations, the chloroform contains the f Generously provided by J. W. Brackett, San Mateo County Coroner Toxicology Laboratory, diphenylhydantoin internal standard. The San Mateo, CA 94403. tubes are shaken for one minute to extract 60 SHIPE AND SAVORY phetamine and 20 ml of chloroform are combined in a 50 ml ground-glass stop­ pered centrifuge tube. The tubes are shaken vigorously for one minute, centri­ fuged and the upper aqueous layer re­ 9 moved by aspiration and discarded. The 14 organic phase is dried by shaking with one g of anhydrous sodium sulfate. A 10 ml aliquot of the chloroform is combined with 0.2 ml acetic anhydride in a 15 ml conical centrifuge tube and the contents evaporated to dryness.
Recommended publications
  • House Bill No.11 (2019)
    LEGISLATURE OF THE STATE OF IDAHO Sixty-fifth Legislature First Regular Session - 2019 IN THE HOUSE OF REPRESENTATIVES HOUSE BILL NO. 11 BY HEALTH AND WELFARE COMMITTEE 1 AN ACT 2 RELATING TO CONTROLLED SUBSTANCES; AMENDING SECTION 37-2705, IDAHO CODE, TO 3 REVISE THE LIST OF SCHEDULE I CONTROLLED SUBSTANCES; AMENDING SECTION 4 37-2709, IDAHO CODE, TO PROVIDE AN EXCLUSION AND TO MAKE A TECHNICAL 5 CORRECTION; AMENDING SECTION 37-2713, IDAHO CODE, TO REVISE THE LIST OF 6 SCHEDULE V DRUGS AND SUBSTANCES; AND DECLARING AN EMERGENCY. 7 Be It Enacted by the Legislature of the State of Idaho: 8 SECTION 1. That Section 37-2705, Idaho Code, be, and the same is hereby 9 amended to read as follows: 10 37-2705. SCHEDULE I. (a) The controlled substances listed in this sec- 11 tion are included in schedule I. 12 (b) Any of the following opiates, including their isomers, esters, 13 ethers, salts, and salts of isomers, esters, and ethers, unless specifically 14 excepted, whenever the existence of these isomers, esters, ethers and salts 15 is possible within the specific chemical designation: 16 (1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-pip- 17 eridinyl]-N-phenylacetamide); 18 (2) Acetylmethadol; 19 (3) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylac- 20 etamide); 21 (4) Allylprodine; 22 (5) Alphacetylmethadol (except levo-alphacetylmethadol also known as 23 levo-alpha-acetylmethadol, levomethadyl acetate or LAAM); 24 (6) Alphameprodine; 25 (7) Alphamethadol; 26 (8) Alpha-methylfentanyl; 27 (9) Alpha-methylthiofentanyl
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • Chloral Hydrate: Summary Report
    Chloral Hydrate: Summary Report Item Type Report Authors Yuen, Melissa V.; Gianturco, Stephanie L.; Pavlech, Laura L.; Storm, Kathena D.; Yoon, SeJeong; Mattingly, Ashlee N. Publication Date 2020-02 Keywords Compounding; Food, Drug, and Cosmetic Act, Section 503B; Food and Drug Administration; Outsourcing facility; Drug compounding; Legislation, Drug; United States Food and Drug Administration; Chloral Hydrate Rights Attribution-NoDerivatives 4.0 International Download date 26/09/2021 09:06:16 Item License http://creativecommons.org/licenses/by-nd/4.0/ Link to Item http://hdl.handle.net/10713/12087 Summary Report Chloral Hydrate Prepared for: Food and Drug Administration Clinical use of bulk drug substances nominated for inclusion on the 503B Bulks List Grant number: 2U01FD005946 Prepared by: University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI) University of Maryland School of Pharmacy February 2020 This report was supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award (U01FD005946) totaling $2,342,364, with 100 percent funded by the FDA/HHS. The contents are those of the authors and do not necessarily represent the official views of, nor an endorsement by, the FDA/HHS or the U.S. Government. 1 Table of Contents REVIEW OF NOMINATION ..................................................................................................... 4 METHODOLOGY ...................................................................................................................
    [Show full text]
  • Glutethimide Market in the United States of America Because of (S 116) and Methyprylon (S 117) Have Been Marketed Serious Side-Effects
    44 H. ISBELL & T. L. CHRUSCIEL 184. Swanson, L. A. & Okada, T. (1963) J. Amer. med. 186. Wilson, J. C. (1963) Amer. J. Psychiat., 120, 600-601 Ass., 184, 780 (Death after withdrawal of mepro- (Status epilepticus associated with withdrawal bamate) from deprol (meprobamate and benactyzine)) 185. Taddei, J. & Parmi, E. (1959) Boll. Soc. ital. Biol. 187. Veress, F., Major, V., Fink, M. & Freedman, A. M. sper., 35, 211-214 (Pharmacological observation (1969) J. clin. Pharmacol., 9, 232-238 (High dose on the meprobamate habit) tybamate therapy of heroin dependence) PIPERIDINEDIONE DERIVATIVES Of the seven drugs listed (Table VII), glutethimide market in the United States of America because of (S 116) and methyprylon (S 117) have been marketed serious side-effects. for the longest time. Originally, both glutethimide and methyprylon were advertised as being " non- REFERENCES barbiturate" hypnotics. Actually both drugs are pharmacologically quite similar to barbiturates and 188. Berger, H. (1961) J. Amer. med. Ass.. 177, 63 glutethimide is more toxic than barbiturates when (Addiction to methyprylon) taken in large doses. Shortly after both glutethimide 189. Horn, M. H. (1968) Fortschr. Neurol. Psychiat.. 36, and methyprylon became available, case reports 310-316 (Einige Aspekte der Methyprylonsucht) began to appear in the literature indicating that the 190. Jensen, R. (1960) N. Z. med. J., 59, 431 (Addiction two drugs caused dependence of the barbiturate- to Nodular. A report of 2 cases) 191. Johnson, F. A. & VanBuren, H. C. (1962) J. Amer. alcohol type in man.1881l95 Glutethimide has been med. Ass., 180, 1024 (Abstinence syndrome shown to induce dependence in dogs and monkeys following glutethimide intoxication) and to suppress abstinence from barbital in physically 192.
    [Show full text]
  • 483 Administrative Records, Texas Department of Criminal Justice
    Consistent with the terms of the Court’s May 22, 2017 scheduling order, the record has been redacted for all information that plaintiff, Texas Department of Criminal Justice (Texas), has identified as confidential. In addition, Defendants have also redacted information that the drug’s supplier and broker have separately advised the agency they consider confidential and private, as well as information the agency itself generally treats as confidential. This information has been redacted pending final FDA’s review of confidentiality claims, and our filing of the record with these redactions does not necessarily reflect our agreement with all of the claims of confidentiality Defendants have received. Defendants explicitly reserve the right to make an independent determination regarding the proper scope of redactions at a later time. Should we identify any of Texas’s redactions that are over-broad or otherwise improper, we will work with Texas’s counsel to revise the redactions in the record. Exhibit 14 FDA 095 Case 1:11-cv-00289-RJL Document 13-3 Filed 04/20/11 Page 1 of 74 CERTJFICATE Pursuant to the provisions ofRule 44 ofthe Federal Rules ofCivil Procedure, I hereby certifY that John Verbeten, Director ofthe Operations and Policy Branch, Division of Import Operations and Policy, Office ofRegional Operations, Office ofRegulatory Affairs, United States Food and Drug Administration, whose declaration is attached, has custody ofofficial records ofthe United States Food and Drug Administration. In witness whereof, I have, pursuant to the provision ofTitle 42, United States Code, Section 3505, and FDA StaffManual Guide 1410.23, hereto set my hand and caused the seal ofthe Department ofHealth and Human Services to be affixed th.is ~oi{.
    [Show full text]
  • Drug/Substance Trade Name(S)
    A B C D E F G H I J K 1 Drug/Substance Trade Name(s) Drug Class Existing Penalty Class Special Notation T1:Doping/Endangerment Level T2: Mismanagement Level Comments Methylenedioxypyrovalerone is a stimulant of the cathinone class which acts as a 3,4-methylenedioxypyprovaleroneMDPV, “bath salts” norepinephrine-dopamine reuptake inhibitor. It was first developed in the 1960s by a team at 1 A Yes A A 2 Boehringer Ingelheim. No 3 Alfentanil Alfenta Narcotic used to control pain and keep patients asleep during surgery. 1 A Yes A No A Aminoxafen, Aminorex is a weight loss stimulant drug. It was withdrawn from the market after it was found Aminorex Aminoxaphen, Apiquel, to cause pulmonary hypertension. 1 A Yes A A 4 McN-742, Menocil No Amphetamine is a potent central nervous system stimulant that is used in the treatment of Amphetamine Speed, Upper 1 A Yes A A 5 attention deficit hyperactivity disorder, narcolepsy, and obesity. No Anileridine is a synthetic analgesic drug and is a member of the piperidine class of analgesic Anileridine Leritine 1 A Yes A A 6 agents developed by Merck & Co. in the 1950s. No Dopamine promoter used to treat loss of muscle movement control caused by Parkinson's Apomorphine Apokyn, Ixense 1 A Yes A A 7 disease. No Recreational drug with euphoriant and stimulant properties. The effects produced by BZP are comparable to those produced by amphetamine. It is often claimed that BZP was originally Benzylpiperazine BZP 1 A Yes A A synthesized as a potential antihelminthic (anti-parasitic) agent for use in farm animals.
    [Show full text]
  • Sedative-Hypnotics: Pharmacology and Use
    CLINICAL REVIEW Sedative-Hypnotics: Pharmacology and Use Norman S. Miller, MD, and Mark S. Gold, MD White Plains, New York, Summit, New Jersey, and Delray Beach, Florida The quest for an ideal sedative-hypnotic drug has been fraught with failure. The goals of the perfect sedative-hypnotic drug are to: (1) produce a transient reduc­ tion in the level of consciousness for the purpose of sedation, calmness, and tran­ quility without lingering aftereffects: (2) produce sleep without the potential to ar­ rest respirations and without aftereffects on sensorium and mood; and (3) produce no abuse, addiction, tolerance, or dependence. Nonetheless, clinical conditions have required the use of sedative-hypnotic drugs in spite of the inher­ ent difficulties with them. The history of sedative-hypnotic drugs is replete with attempts to produce a safe and effective drug. The introduction of one sedative-hypnotic drug for an­ other has been heralded by unguarded optimism and misguided claims. History has repeated itself with each new drug. Toxicities, abuse, addiction, and develop­ ment of tolerance and dependence have remained in force for each drug that has appeared on the market. Only minor variations on a theme have differentiated one drug from another as the essential features have remained in force. he members of the class of sedative-hypnotic drugs are were initially considered to have less potential for abuse, Tremarkably similar in their pharmacological proper­ they may be equal to the sedative-hypnotic drugs in these ties but vary considerably in their chemical structure. The respects.3-4 method of classification arose primarily as an attempt to Other members of the sedative-hypnotic class are chlo­ categorize the drugs according to the subjective and be­ ral hydrate, ethchlorvynol, glutethimide, meprobamate, havioral effects produced by them, that is, sedation and methyprylon, paraldehyde, and triclofos.
    [Show full text]
  • Hypnotic Drugs RUSSELL R
    Postgrad Med J: first published as 10.1136/pgmj.46.535.314 on 1 May 1970. Downloaded from Pcstgraduate Medical Journal (May 1970) 46, 314-317. CURRENT SURVEY Hypnotic drugs RUSSELL R. MILLER* DIRK V. DEYOUNG Pharm. D. M.D. Director, Drug Communications Study, Assistant Medical Director, University of Chicago Continental Assurance Company, Chicago JAMES PAXINOS B.S (Pharm.) Assistant Director for Clinical Services, Department ofPharmacy, University of Chicago Hospitals and Clinics THIS review will treat the more commonly prescribed Human pharmacology hypnotic agents and their sleep-inducing properties. In the past, hypnotics have been divided into Hypnotic agents that are seldom used (paraldehyde), barbiturates and non-barbiturates. This classification, drugs that are not singularly soporific but may be based on chemical structure, has little contemporary used either alone or as adjuncts in inducing sleep [e.g. clinical significance since compounds in each group meprobamate (Equanil, Miltown), chlordiazepoxide have essentially the same qualitative pharmacologic (Librium) and diazepam (Valium)] and drugs that properties. Naturally, there are quantitative differ- copyright. have little soporific effect [antihistamines, bromides ences in onset and duration of action. and methylparafynol (Oblivon, Dormison) (Lasagna, 1954)] will not be discussed. Onset of action Indications Onset is generally rapid with liquid preparations Insomnia is an extremely common complaint with such as syrup of chloral hydrate (Noctec, Somnos), which are confronted.
    [Show full text]
  • A Summary of California's Alcohol and Drug Abuse Laws
    If you have issues viewing or accessing this file contact us at NCJRS.gov. A SUMMARY OF CALIFORNIA'S ALCOHOL AND DRUG ABUSE LAWS Prepared pursuant to SB 2599 (Seymour), (Chapter 983, Statutes of 1988) Prepared by: SENATE OFFICE OF RESEARCH Elisabeth Kersten, Director June 3D, 1989 462-8 127464 U.S. Department of Justice National Institute of Justice This document has been reproduced exactly as received from the person or organization originating It. Points of view or opinions stated In this document are those of the authors and do not necessarily represent the official position or policies of the National Institute of Justice. Permission to reproduce this copyrighted material has been granted bl:: California Legislature to the National Criminal Justice Reference Service (NCJRS). Further reproduction outside of the NCJRS system requires permis­ sion of the copyright owner. A SUMMARY OF CALIFORNIA'S ALCOHOL AND DRUG ABUSE LAWS Prepared pursuant to SB 2599 (Seymour), (Chapter 983, Statutes of 1988) June 30, 1989 Prepared by: SENATE OFFICE OF RESEARCH, Ken Hurdle, Project Director, Kim Connor, Dan Englund, Dolores Sanchez, Lenore Tate Edited by: Judith A. Ryder, Thomas F. Wilspn ~;:- ~~~: ~M8ERS: ~ILLIAM A. CRAVEN to DAVIS CALIFORNIA LEGISLATURE VADIE DEDDEH TERRI DELGADILLO ~'ECIL GREEN , COMMITTEE CONSULTANT ;'ARY HART !ILL" LOCKYER STATE CAPITOL. ROOM 3074 !'E8ECCA MORGAN SACRAMENTO. CA 95814 ilCHOLAS PETRIS (916) 445-4264 to ROYCE ~ANEWATSON ~ SENATE SELECT COMMITTEE ~ ON ~ ~:, SUBSTANCE ABUSE r~, ~ t; JOHN SEYMOUR ~: !i CHAIRMAN 1 ~~ tl December 19, 1989 r1 \i ~ ~, As Chairman of the Senate Select Committee on Substance l\ Abuse, I am pleased to participate with the Senate Office of I' Research in the release of A Summary of California's Alcohol ~ and Drug Abuse Laws.
    [Show full text]
  • Depressants Sedative Hypnotics
    Psyc 470 – Introduction to Chemical Addictions Alcohol • Oldest Sedative Hypnotic Depressants • Used thousands of years Sedative Hypnotics • Used mostly for self medication Psychology 470 Introduction to Chemical Additions Steven E. Meier, Ph.D. Listen to the audio lecture while viewing these slides 1 2 Psyc 470 – Introduction to Chemical Addictions Psyc 470 – Introduction to Chemical Addictions Used for Many Things General Names • To relieve stress •Downers • Induce sleep • Sedatives • Reduce anxiety •Hypnotics • Minor Tranquilizers • Anxiolytics • Anti Anxiety Medications 3 4 Psyc 470 – Introduction to Chemical Addictions Psyc 470 – Introduction to Chemical Addictions Classes of Compounds Based Historically Non-Barbiturates • Non-Barbiturates • Use began before 1900 • Barbiturates • Many compounds • Antianxiety Medications/Minor •Bromides * Tranquilizers • Chloral Hydrate * • Paraldehyde* •Urethane • Sulfonal • Most are not used today 5 6 1 Psyc 470 – Introduction to Chemical Addictions Psyc 470 – Introduction to Chemical Addictions Bromides Problems • Sodium Bromide • Lots of side effects • One of the earliest Sedative Hypnotics • Takes a long time to administer and • Behaves like a chloride ion eliminate from the system • Shuts down the action potential •Can be toxic • Is eliminated slowly • Can still be used for epileptic seizures • Need to gradually increase the dosage and sedation but other drug groups are over days (titrate the patient) until the better desired effect occurs • Not used much today 7 8 Psyc 470 – Introduction to Chemical Addictions Psyc 470 – Introduction to Chemical Addictions Chloral Hydrate (Noctec) Paraldehyde • Oldest sleep inducing (hypnotic) depressant • Is a polymer of acetaldehyde • First synthesized in 1832 • Occasionally used to treat DT’s • Induces sleep in approximately ½ hour • Therapeutic Doses • Sleep occurs in about 15 minutes • Little effect on respiration or BP • Drug is metabolized to acetaldehyde by •Toxic Doses the liver and eliminated through the • Severe respiration depression and low BP lungs – gives an odor.
    [Show full text]
  • Clinical Evaluation of Methyprylon (Noludar®) + As A
    CLINICAL EVALUATION OF METHYPRYLON (NOLUDAR| AS A PREANAESTHETIC SEDATIVE HYPNOq~]C ALLEN B. DoBKn% M.D.,* and GORDON M. WYANT, F.F.A.I~C S.* with clinical assistance of FRAN~r DYCK** MANY psychological factors affect the patient who requires an anaesthetic and an operation. To varying degrees these may influence the response to a curative or palhatlve operation, either to' advantage or to disadvantage (I 1). These factors are of such an intangible nature that the wisest clinician has difficulty when he attempts to measure them either subjectively or objectively (2). The determina- tion of the effect of drugs upon psychological changes induced by a stress situa- tion in a hospital environment multaphes the complexity of the mehsurements (3). It is exceedingly difficult for the elimcal inveshgator to eliminate prejudice and bias, and it is even more difficult to formulate reliable and vahd objective and subjechve means fo" determining the value of procedures designed to influence favourably the psychological and physiological ~esponse of a patient to operation (4, 5). A few investigators have recently tackled "this problem in a way which is unique in clinical medicine (6, 7, 8, 9, 10). They used combinations of sedative-hypnotic drugs and placebos in double blind studies. The results, of such studies have provided us with lughly revealing information. Herring (11) has studied this problem on a a even wider base. Iu evaluating the effects of premedlcant drugs he has referred to the psychological factors as "predictor'" variables and to the factors representing the surgical response as "criterion'" variables He divided the predictor variables into two categories: first, those measuring personality varlable,~ which may be elicited from patients prior to an operation, and second, the judgments made by psychologists using these measurements m an effort to predict responses during the operation.
    [Show full text]
  • Drugs and Human Performance Fact Sheets Technical Report Documentation Page 1
    NATIONAL HIGHWAY TRAFFIC SAFETY ADMINISTRATION Drugs and Human Performance Fact Sheets Technical Report Documentation Page 1. Report No. 2. Government Accession No. 3. Recipient's Catalog No. DOT HS 809 725 4. Title and Subtitle 5. Report Date Drugs and Human Performance Fact Sheets April 2014 (Revised) 6. Performing Organization Code 7. Author(s) 8. Performing Organization Report No. COUPER, Fiona J. and LOGAN, Barry K 9. Performing Organization Name and Address 10. Work Unit No. (TRAIS) Washington State PatrolForensic Laboratory Services Bureau 2203 Airport Way S., Seattle, WA 98134 11. Contract or Grant No. 12. Sponsoring Agency Name and Address’ 13. Type of Report and Period Covered National Highway Traffic Safety Administration Final Report; 400 Seventh St., SW. August 2000-March 2004 Washington, DC 20590 14. Sponsoring Agency Code 15. Supplementary Notes The following toxicologists made significant contributions to both the drafting and review of the Fact Sheets: Michael Corbett Ph.D., Laurel Farrell MS., Marilyn Huestis Ph.D., Wayne Jeffrey MS, and Jan Raemakers, Ph.D. James F.Frank Ph.D. served as the NHTSA Contracting Officer's Technical Representative. 16. Abstract A panel of international experts on drug-impaired driving met in Seattle during August 2000 to review developments in the field of drugs and human performance over the last 10 years; to identify the specific effects that both illicit and prescription drugs have on driving; and to develop guidance for others when dealing with drug-impaired driving problems. Delegates represented the fields of psychopharmacology, behavioral psychology, drug chemistry, forensic toxicology, medicine, and law enforcement experts trained in the recognition of drug effects on drivers in the field.
    [Show full text]